Vontobel Holding
ENGN icon

Vontobel Holding’s enGene Therapeutics ENGN Stock Holding History

Vontobel Holding’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,417
Closed -$69.3K – 1107
2024
Q4 		$69.3K Buy
+10,417
New +$80.9K ﹤0.01% 1056

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vontobel Holding's ENGN Position: Q1 2025 in Review

Vontobel Holding sold out of enGene Therapeutics (ENGN) in Q1 2025, closing a stake of 10,417 shares — an estimated $69.3K sold.

Vontobel Holding first reported a position in ENGN in Q4 2024 and held it in 1 quarter. The position peaked at $69.3K in Q4 2024. 31 funds tracked by Wall St. Rank hold ENGN as of Q1 2025.

  • Vontobel Holding reported no remaining enGene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Vontobel Holding sold 10,417 enGene Therapeutics shares in Q1 2025, an estimated $69.3K.
  • Vontobel Holding first reported a position in enGene Therapeutics in Q4 2024 and held it in 1 quarter.
  • Vontobel Holding's enGene Therapeutics position peaked at $69.3K in Q4 2024.
  • 31 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2025.

Based on Vontobel Holding's 13F filing for Q1 2025, filed 28 Apr 2025.